Table 1. Classification of AML responses... | American Society of Hematology

Table 1.

Classification of AML responses to CC-90009

Patient ID	LSC17 classification	RF mean engraftment (%)			RR (%)	BM mean engraftment (%)			RR (%)	In vivo response
Patient ID	LSC17 classification	CC-90009	Vehicle	P	RR (%)	CC-90009	Vehicle	P	RR (%)	In vivo response
12	LSC17^hi	0.0	32.2	<.05	100	0.0	2.2	<.05	99	R
20	LSC17^hi	0.1	86.6	<.0001	100	0.0	14.1	<.0001	100	R
8	LSC17^hi	0.1	75.0	<.0001	100	0.0	4.5	NS	100	R
37	LSC17^hi	0.1	65.3	<.01	100	0.0	48.6	<.0001	100	R
38	LSC17^hi	0.3	85.0	<.0001	100	0.1	67.7	<.0001	100	R
15	LSC17^lo	0.6	88.2	<.0001	99	0.2	57.2	<.0001	100	R
34	LSC17^hi	0.7	44.5	<.0001	99	0.1	7.1	<.05	98	R
5	LSC17^hi	3.7	96.9	<.0001	96	6.7	76.1	<.0001	91	R
11	LSC17^lo	3.2	81.8	<.0001	96	1.4	81.9	<.0001	98	R
21	LSC17^hi	3.0	77.3	<.0001	96	0.5	64.6	<.0001	99	R
10	LSC17^hi	2.6	54.5	<.05	95	0.6	45.5	<.0001	99	R
9	LSC17^hi	3.6	72.0	<.0001	95	0.32	16.7	<.01	98	R
1	LSC17^hi	4.6	79.0	<.0001	94	2.0	66.5	<.0001	97	R
26	LSC17^hi	3.6	41.2	<.001	91	0.4	30.6	<.01	99	R
7	LSC17^lo	8.8	91.8	<.0001	91	4.4	38.3	<.001	89	R
36	LSC17^lo	7.4	52.3	<.05	86	2.7	25.8	<.01	96	R
18	LSC17^hi	24.2	91.3	NS	74	3.1	78.5	<.01	96	R
25	LSC17^hi	18.5	66.7	<.001	72	12.8	38.2	<.0001	67	R
30	LSC17^hi	11.1	37.1	>.05	70	5.0	34.5	<.05	86	R
17	LSC17^lo	12.7	40.9	<.001	69	8.4	22.3	<.05	62	R
14	LSC17^lo	23.1	74.0	<.001	69	1.6	64.6	<.01	98	R
13	LSC17^lo	27.4	78.0	<.0001	65	19.0	82.6	<.0001	77	R
3	LSC17^hi	16.4	42.0	<.05	61	8.0	29.6	<.05	73	R
27	LSC17^hi	31.6	65.0	<.01	52	3.3	23.6	<.001	86	R
6	LSC17^hi	49.8	92.0	<.01	46	2.9	57.0	<.0001	95	PR
24	LSC17^hi	6.2	7.0	NS	9	1.7	48.4	<.05	97	PR
4	LSC17^hi	56.8	99.0	<.01	42	46.5	97.6	<.01	52	PR
28	LSC17^hi	76	91.0	NS	17	35.8	81.5	<.0001	56	PR
2	LSC17^hi	84.4	97.2	NS	13	27.6	84.5	<.01	67	PR
19	LSC17^hi	80.6	88.3	<.01	9	64.7	87.1	<.05	26	PR
32	LSC17^hi	84.2	88.0	NS	4	62.0	86.6	<.05	28	PR
35	LSC17^lo	93.2	94.3	NS	1	66.4	83.3	<.05	20	PR
16	LSC17^hi	96.6	96.2	NS	0	92.4	94.6	NS	2	NR
31	LSC17^hi	98.0	97.5	NS	0	96.8	97.4	NS	1	NR
23	LSC17^hi	76.8	63.5	NS	0	14.5	4.1	NS	0	NR

Patient ID	LSC17 classification	RF mean engraftment (%)			RR (%)	BM mean engraftment (%)			RR (%)	In vivo response
Patient ID	LSC17 classification	CC-90009	Vehicle	P	RR (%)	CC-90009	Vehicle	P	RR (%)	In vivo response
12	LSC17^hi	0.0	32.2	<.05	100	0.0	2.2	<.05	99	R
20	LSC17^hi	0.1	86.6	<.0001	100	0.0	14.1	<.0001	100	R
8	LSC17^hi	0.1	75.0	<.0001	100	0.0	4.5	NS	100	R
37	LSC17^hi	0.1	65.3	<.01	100	0.0	48.6	<.0001	100	R
38	LSC17^hi	0.3	85.0	<.0001	100	0.1	67.7	<.0001	100	R
15	LSC17^lo	0.6	88.2	<.0001	99	0.2	57.2	<.0001	100	R
34	LSC17^hi	0.7	44.5	<.0001	99	0.1	7.1	<.05	98	R
5	LSC17^hi	3.7	96.9	<.0001	96	6.7	76.1	<.0001	91	R
11	LSC17^lo	3.2	81.8	<.0001	96	1.4	81.9	<.0001	98	R
21	LSC17^hi	3.0	77.3	<.0001	96	0.5	64.6	<.0001	99	R
10	LSC17^hi	2.6	54.5	<.05	95	0.6	45.5	<.0001	99	R
9	LSC17^hi	3.6	72.0	<.0001	95	0.32	16.7	<.01	98	R
1	LSC17^hi	4.6	79.0	<.0001	94	2.0	66.5	<.0001	97	R
26	LSC17^hi	3.6	41.2	<.001	91	0.4	30.6	<.01	99	R
7	LSC17^lo	8.8	91.8	<.0001	91	4.4	38.3	<.001	89	R
36	LSC17^lo	7.4	52.3	<.05	86	2.7	25.8	<.01	96	R
18	LSC17^hi	24.2	91.3	NS	74	3.1	78.5	<.01	96	R
25	LSC17^hi	18.5	66.7	<.001	72	12.8	38.2	<.0001	67	R
30	LSC17^hi	11.1	37.1	>.05	70	5.0	34.5	<.05	86	R
17	LSC17^lo	12.7	40.9	<.001	69	8.4	22.3	<.05	62	R
14	LSC17^lo	23.1	74.0	<.001	69	1.6	64.6	<.01	98	R
13	LSC17^lo	27.4	78.0	<.0001	65	19.0	82.6	<.0001	77	R
3	LSC17^hi	16.4	42.0	<.05	61	8.0	29.6	<.05	73	R
27	LSC17^hi	31.6	65.0	<.01	52	3.3	23.6	<.001	86	R
6	LSC17^hi	49.8	92.0	<.01	46	2.9	57.0	<.0001	95	PR
24	LSC17^hi	6.2	7.0	NS	9	1.7	48.4	<.05	97	PR
4	LSC17^hi	56.8	99.0	<.01	42	46.5	97.6	<.01	52	PR
28	LSC17^hi	76	91.0	NS	17	35.8	81.5	<.0001	56	PR
2	LSC17^hi	84.4	97.2	NS	13	27.6	84.5	<.01	67	PR
19	LSC17^hi	80.6	88.3	<.01	9	64.7	87.1	<.05	26	PR
32	LSC17^hi	84.2	88.0	NS	4	62.0	86.6	<.05	28	PR
35	LSC17^lo	93.2	94.3	NS	1	66.4	83.3	<.05	20	PR
16	LSC17^hi	96.6	96.2	NS	0	92.4	94.6	NS	2	NR
31	LSC17^hi	98.0	97.5	NS	0	96.8	97.4	NS	1	NR
23	LSC17^hi	76.8	63.5	NS	0	14.5	4.1	NS	0	NR

LSC17^hi, high LSC17 score; LSC17^lo, low LSC17 score; NS, no significant difference between CC-90009- and vehicle-treated mice or <20% relative reduction in both RF and BM; PR, 20% to 50% RR in RF or >20% RR in BM only; R, >50% RR in RF; RF, injected right femur; RR, relative reduction.

View Large

This Feature Is Available To Subscribers Only